Physiometrix, Inc. announced that it has signed an amendment to its U.S. distribution agreement with Baxter Healthcare Corporation for the PSA 4000 level of sedation monitor.

The highlights of this enhanced agreement include: Targeted sales, marketing and product development milestones; Segmentation of the Operating Room (OR), Intensive Care Unit (ICU) and Interventional Sedation Unit (ISU) -Markets to ensure success in each area; Significant sales time dedicated to the PSA 4000; Ample minimum-purchase requirements; Innovative marketing programs to promote the Physiometrix technology; Expansion of the territory to include Canada.

“This new agreement reflects a renewed commitment by Baxter to our technology,” said John A. Williams, president and chief executive officer of Physiometrix. “We will benefit from increased selling time, painstaking marketing initiatives and a plan that delivers results. We are very confident about our future and the potential of our technology. ”

“Moreover, the new PSA 4000 with Frontal Array is being received enthusiastically by clinicians. We are seeing a robust synergy between the Operating Room and Intensive Care Units that we intend to leverage. Baxter's sales organization is wholly committed to level-of-sedation monitoring. ”

“We believe that a dedicated approach to the three distinct markets will yield the best possible outcome for our shareholders and the greatest potential for wider market acceptance of PSA 4000,” added Williams.”